NCT03480971 - Treatment of Radiation and Cisplatin Induced Toxicities with Tempol | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

May 13, 2019

Primary Completion Date

July 31, 2025

Study Completion Date

December 31, 2025

Conditions

MucositisNephrotoxicityOtotoxicity

Interventions

DRUG

Tempol

Investigational product is Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl) oral solution. Tempol solution is an orange-colored, aqueous solution containing 7% Tempol along with xanthan gum, xylitol, aspartame, acesulfame potassium, sodium saccharin, alcohol, peppermint and wintergreen oils.

DRUG

Placebo Solution

The placebo contains the same excipients as the active product plus FD\&C Yellow #6 for color matching.

Trial Locations (9)

10461

RECRUITING

Montefiore Medical Center-Einstein Campus, The Bronx

27157

RECRUITING

Wake Forest University Health Sciences, Winston-Salem

92093

RECRUITING

UCSD, La Jolla

93454

RECRUITING

Central Coast Medical Oncology, Santa Maria

RECRUITING

Mission Hope Health Center, Santa Maria

94158

ACTIVE_NOT_RECRUITING

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco

95340

RECRUITING

Mercy Medical Center, Merced

98195

RECRUITING

Seattle Cancer Care Alliance, Seattle

RECRUITING

University of Washington Medical Center, Seattle